KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis.

Soumyajit Roy, Angela Y Jia, Nicholas G Zaorsky, Daniel E Spratt

Int J Radiat Oncol Biol Phys S0360-3016(26)00730-3

PMID42176865
PMCID-
DOI10.1016/j.ijrobp.2026.05.014
发表日期2026-05-23
摘要

摘要

PURPOSE: Recently, results from National Surgical Adjuvant Breast and Bowel Project; Radiation Therapy Oncology Group; Gynecologic Oncologic Group (NRG/RTOG) 0924, the largest randomized trial to evaluate the benefit of whole-pelvic radiation therapy (WPRT) in localized prostate cancer, were presented. We conducted an aggregate meta-analysis of all phase III randomized trials to determine the impact of WPRT on oncologic outcomes. METHODS: PubMed via MEDLINE, clinicaltrials.gov, and conference proceedings were systematically searched for randomized trials of ±WPRT in localized prostate cancer conducted between 1980 and 2025. Random-effects models were used to generate pooled hazard ratios (HRs) with 95% CIs. Heterogeneity was assessed with I2 statistics, and leave-one-out sensitivity analyses were performed. Meta-regression was performed to assess the influence of the proportion of patients with Gleason score 7 to 10, use of androgen deprivation therapy, radiation therapy dose, and field size. Endpoints assessed included overall survival, a biochemical-based endpoint, referred to as biochemical recurrence, and distant metastasis. RESULTS: Four randomized trials were identified (n = 4465 patients), including 3 multicenter cooperative group trials Urogenital Tumor Study Group-French Association of Urology (GETUG-AFU-01, RTOG 9413, and RTOG 0924) and 1 single-institution trial Prostate-Only versus Whole-Pelvic Radiation Therapy (POP-RT). WPRT did not improve overall survival (HR, 1.05; 95% CI, 0.95-1.16; I2 = 0%), biochemical recurrence (HR, 0.82; 95% CI, 0.63-1.07; I2 = 76%), or distant metastasis (HR, 0.88; 95% CI, 0.58-1.34; I2 = 68%). The high rates of heterogeneity observed were due primarily to the POP-RT trial. In sensitivity analyses, excluding POP-RT heterogeneity was eliminated (HR for biochemical recurrence was 0.91 [95% CI, 0.81-1.02; I2 = 0%]; HR for distant metastasis was 1.06 [95% CI, 0.87-1.29; I2 = 0%]). Meta-regression found no significant modifying effect of any covariables assessed. CONCLUSIONS: This aggregate meta-analysis did not demonstrate any meaningful benefit of WPRT over prostate-only radiation therapy in unselected localized prostate cancer. Individual patient data meta-analysis is warranted to understand whether any subgroup consistently derives benefit from WPRT.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。